LECCIÓN

2

MÓDULO

6

Paradigmas experimentales y biomarcadores emergentes en esclerosis múltiple: qué y cómo hemos avanzado en la obtención de nuevos fármacos
Dr. Carlos Matute

Laboratory of Neurobiology, Achucarro Basque Center for Neuroscience, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV-EHU), Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Leioa, Bizkaia

Referencias bibliográficas

  1. Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018 Feb 21;97(4):742-68. [Pubmed]
  2. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006 Oct 5;52(1):61-76. [Pubmed]
  3. Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016 Nov 15;87(20):2074-81. [Pubmed]
  4. Matute C, Alberdi E, Domercq M, Sánchez-Gómez MV, Pérez-Samartín A, Rodríguez-Antigüedad A, Pérez-Cerdá F. Excitotoxic damage to white matter. J Anat. 2007 Jun;210(6):693-702. [Pubmed]
  5. Matute C, Torre I, Pérez-Cerdá F, Pérez-Samartín A, Alberdi E, Etxebarria E, et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci. 2007 Aug 29;27(35):9525-33. [Pubmed]
  6. Saab AS, Tzvetavona ID, Trevisiol A, Baltan S, Dibaj P, Kusch K, et al. Oligodendroglial NMDA Receptors Regulate Glucose Import and Axonal Energy Metabolism. Neuron. 2016 Jul 6;91(1):119-32. [Pubmed]
  7. Ghareghani M, Ghanbari A, Eid A, Shaito A, Mohamed W, Mondello S, Zibara K. Hormones in experimental autoimmune encephalomyelitis (EAE) animal models. Transl Neurosci. 2021 May 6;12(1):164-89. [Pubmed]
  8. Montilla A, Zabala A, Er-Lukowiak M, Rissiek B, Magnus T, RodrÍguez-Iglesias N, ET AL. Microglia and meningeal macrophages depletion delays the onset of experimental autoimmune encephalomyelitis. Cell Death Dis. 2023 Jan 12;14(1):16. [Pubmed]
  9. Zirngibl M, Assinck P, Sizov A, Caprariello AV, Plemel JR. Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination. Mol Neurodegener. 2022 May 7;17(1):34. [Pubmed]
  10. Bernal-Chico A, Manterola A, Cipriani R, Katona I, Matute C, Mato S. P2x7 receptors control demyelination and inflammation in the cuprizone model. Brain Behav Immun Health. 2020 Mar 28;4:100062. Erratum in: Brain Behav Immun Health. 2021 Dec 23;19:100408. [Pubmed]
  11. Serrano-Regal MP, Bayón-Cordero L, Chara Ventura JC, Ochoa-Bueno BI, Tepavcevic V, Matute C, Sánchez-Gómez MV. GABAB receptor agonist baclofen promotes central nervous system remyelination. Glia. 2022 Dec;70(12):2426-40. [Pubmed]
  12. Biernacki T, Kokas Z, Sandi D, Füvesi J, Fricska-Nagy Z, Faragó P, et al. Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations. Int J Mol Sci. 2022 Mar 21;23(6):3383. [Pubmed]
  13. Yang J, Hamade M, Wu Q, Wang Q, Axtell R, Giri S, Mao-Draayer Y. Current and Future Biomarkers in Multiple Sclerosis. Int J Mol Sci. 2022 May 24;23(11):5877. [Pubmed]
  14. Selmaj KW, Mycko MP, Furlan R, Rejdak K. Fluid phase biomarkers in multiple sclerosis. Curr Opin Neurol. 2022 Jun 1;35(3):286-92. [Pubmed]
  15. Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli Ö, Maceski A, et al.; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022 Mar;21(3):246-57. [Pubmed]